Anhui Huaheng Biotechnology Co. Ltd. A (688639) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Anhui Huaheng Biotechnology Co. Ltd. A ¥16.20, price ¥18.29, upside -11.4%, quality 23 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Anhui Huaheng Biotechnology Co. Ltd. A for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range ¥15.40 – ¥84.30 · fair‑value band ¥14.72 – ¥20.25 · the ¥18.29 price screens above the ¥16.20 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Follow Anhui Huaheng Biotechnology Co. Ltd. A in your weekly email
Every Wednesday you see whether Anhui Huaheng Biotechnology Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Anhui Huaheng Biotechnology Co., Ltd. engages in the research and development, production, and sale of bio-based products through bio-manufacturing in China and internationally.
Show more
Anhui Huaheng Biotechnology Co., Ltd. engages in the research and development, production, and sale of bio-based products through bio-manufacturing in China and internationally. The company offers amino acid products, including the alanine series, L-valine, isoleucine, tryptophan, and arginine; vitamin products, such as D-calcium pantothenate, D-panthenol, and inositol; bio-based new material monomers, including 1,3-propanediol and succinic acid; and other products, including malic acid and arbutin. Its products are used in daily chemical products, medicine, health and personal care products, cosmetic products, food additives, feeds, animal nutrition, plant nutrition, and functional food and nutrition. The company was formerly known as Anhui Huaheng Biological Engineering Co., Ltd. and changed its name to Anhui Huaheng Biotechnology Co., Ltd. in November 2013. The company was founded in 2005 and is based in Hefei, China.
Stock analysis
Anhui Huaheng Biotechnology Co. Ltd. A (688639) currently trades at ¥18.29, while our model-based Fair Value estimate is ¥16.20, implying the stock looks roughly 12.9% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥21.88 per share, and 2 of the 14 models we run sit above the ¥18.29 price.
Bear case: the Dividend Discount group reads lowest at ¥6.70, and 12 of the 14 models stay below the price. Evidence for this calculation is medium.
Scenario range: ¥14.72 (bear) to ¥20.25 (bull), the price of ¥18.29 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Anhui Huaheng Biotechnology Co. Ltd. A reported revenue of 2.9B CNY in FY2025 versus 954M CNY in FY2021, a compound +31.6%/yr. Reported net income was 132M CNY in FY2025, compounding −5.8%/yr from FY2021.
Key figures
Market cap 4.6B CNY (≈ $687M) · P/E ratio 36.6 · P/S ratio 1.69 · EPS (TTM) ¥0.5000 · Dividend yield 0.9% · Net margin 4.6% · Return on equity 4.3% · Return on assets (EBIT) 9.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 56% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −11%, 688639 screens richer than that median.
Fair Value models
Bear ¥14.72Fair Value ¥16.20Bull ¥20.25
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.2487 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.52/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+31.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+42.5%
Start year 2020 (pandemic). Over 10 years: +27.4% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−5.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−6.6%
Dividend (yield on the price)0.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−7% vs 0%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.27% → 5%
Compare Anhui Huaheng Biotechnology Co. Ltd. A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score23 · Bottom 25%
Fair Value upside−11% · Above median
Profitability
Return on equity (TTM)4% · Above median
Return on assets2% · Above median
Net margin (TTM)4% · Below median
Operating margin (TTM)8% · Above median
Growth and dividend
Revenue growth12% · Above median
Dividend yield (TTM)0.9% · Below median
Balance sheet
Debt / equity0.59× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Anhui Huaheng Biotechnology Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688639
Frequently asked questions
Is Anhui Huaheng Biotechnology Co. Ltd. A (688639) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of ¥16.20 versus a price of ¥18.29, about −11% upside (overvalued).
What is the fair value of 688639?
Our model-based fair value for Anhui Huaheng Biotechnology Co. Ltd. A is ¥16.20 (as of Sep 23, 2026), built from audited fundamentals. The current price: ¥18.29.
What is the quality score of 688639?
Anhui Huaheng Biotechnology Co. Ltd. A has a Quality Score of 23/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Anhui Huaheng Biotechnology Co. Ltd. A (688639)?
Our model-based price target is the fair value of ¥16.20 (as of Sep 23, 2026) from 16 valuation models. Cautious scenario ¥14.72, optimistic scenario ¥20.25. It is a calculation from audited fundamentals, not an analyst target.
What is the Anhui Huaheng Biotechnology Co. Ltd. A stock forecast for 2026?
Our models put fair value at ¥16.20, about −11% upside versus a price of ¥18.29 (overvalued). Cautious scenario ¥14.72, optimistic scenario ¥20.25. The calculation is refreshed regularly with new filings.
What is the revenue of Anhui Huaheng Biotechnology Co. Ltd. A (688639)?
Anhui Huaheng Biotechnology Co. Ltd. A reported trailing-twelve-month revenue of about 2.9B CNY (latest available figure, as of Sep 23, 2026).
Does Anhui Huaheng Biotechnology Co. Ltd. A pay a dividend?
Anhui Huaheng Biotechnology Co. Ltd. A currently shows a dividend yield of about 0.87% relative to its recent price (as of Sep 23, 2026).
What is the intrinsic value of Anhui Huaheng Biotechnology Co. Ltd. A (688639)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Anhui Huaheng Biotechnology Co. Ltd. A it is ¥16.20 per share (as of Sep 23, 2026), against a price of ¥18.29. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Anhui Huaheng Biotechnology Co. Ltd. A stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 688639 trades above its calculated fair value: price ¥18.29, fair value ¥16.20, a gap of about −11% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688639?
No. The price is what the market pays today (¥18.29); the fair value is what the company's own numbers justify (¥16.20). For Anhui Huaheng Biotechnology Co. Ltd. A the two are ¥2.09 per share apart. That gap is exactly why we show both numbers side by side.
How much is Anhui Huaheng Biotechnology Co. Ltd. A worth?
The market values Anhui Huaheng Biotechnology Co. Ltd. A at about 4.6B CNY (market capitalisation, as of Sep 23, 2026). Per share that is ¥18.29; our models calculate a fair value of ¥16.20 per share.
What do the bullish and bearish scenarios say about 688639?
Our models span a range for Anhui Huaheng Biotechnology Co. Ltd. A: cautious scenario ¥14.72, base ¥16.20, optimistic ¥20.25 per share (as of Sep 23, 2026, price ¥18.29). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688639?
Anhui Huaheng Biotechnology Co. Ltd. A trades at a price-to-earnings ratio of 36.6 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥16.20 is built from several models across several years. Other multiples: P/B 1.7, P/S 1.6, EV/EBITDA 15.1.
How solid is the balance sheet of Anhui Huaheng Biotechnology Co. Ltd. A (688639)?
Balance-sheet figures for Anhui Huaheng Biotechnology Co. Ltd. A (as of Sep 23, 2026): return on equity 4.3%, debt of 0.59 per unit of equity. They feed the Quality Score of 23/100, which measures business quality independently of the share price.
How far is 688639 from its 52-week high?
Anhui Huaheng Biotechnology Co. Ltd. A trades at ¥18.29, about 56% below its 52-week high of ¥41.10 and 19% above the low of ¥15.40 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of ¥16.20 is for.
Which stocks are comparable to Anhui Huaheng Biotechnology Co. Ltd. A?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Anhui Huaheng Biotechnology Co. Ltd. A stock attractive at the current price?
The data as of Sep 23, 2026: price ¥18.29, calculated fair value ¥16.20 (−11%), Quality Score 23/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688639 calculated?
We run Anhui Huaheng Biotechnology Co. Ltd. A through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥16.20, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Anhui Huaheng Biotechnology Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Anhui Huaheng Biotechnology Co. Ltd. A (688639)?
The closing price on Sep 23, 2026 was ¥18.29. Our model-based fair value is ¥16.20, about −11% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Anhui Huaheng Biotechnology Co. Ltd. A right now?
The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Where does the earnings growth of Anhui Huaheng Biotechnology Co. Ltd. A (688639) come from?
Earnings per share at Anhui Huaheng Biotechnology Co. Ltd. A grew +6.9 % a year from 2014 to 2025. Broken into its drivers: revenue per share +11.5 %, EBIT margin −3.9 %, tax rate +0.7 %, residual (interest, one-offs) −0.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Anhui Huaheng Biotechnology Co. Ltd. A
How large is the market capitalisation of Anhui Huaheng Biotechnology Co. Ltd. A (688639)?
The market capitalisation of Anhui Huaheng Biotechnology Co. Ltd. A is 4.6B CNY (≈ $687M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Anhui Huaheng Biotechnology Co. Ltd. A (688639)?
The price-to-sales ratio of Anhui Huaheng Biotechnology Co. Ltd. A is 1.69 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Anhui Huaheng Biotechnology Co. Ltd. A (688639)?
Earnings per share at Anhui Huaheng Biotechnology Co. Ltd. A are ¥0.5000 (price ÷ EPS = P/E 36.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Anhui Huaheng Biotechnology Co. Ltd. A (688639)?
The dividend yield of Anhui Huaheng Biotechnology Co. Ltd. A is 0.9% (payout 32.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Anhui Huaheng Biotechnology Co. Ltd. A (688639)?
The net margin of Anhui Huaheng Biotechnology Co. Ltd. A is 4.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Anhui Huaheng Biotechnology Co. Ltd. A (688639)?
The return on equity (ROE) of Anhui Huaheng Biotechnology Co. Ltd. A is 4.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Anhui Huaheng Biotechnology Co. Ltd. A (688639)?
On an EBIT basis the return on assets of Anhui Huaheng Biotechnology Co. Ltd. A is 9.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Anhui Huaheng Biotechnology Co. Ltd. A (688639)?
The operating margin of Anhui Huaheng Biotechnology Co. Ltd. A is 7.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Anhui Huaheng Biotechnology Co. Ltd. A (688639)?
Revenue at Anhui Huaheng Biotechnology Co. Ltd. A is growing +12.3% versus a year earlier (3y avg +26.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Anhui Huaheng Biotechnology Co. Ltd. A (688639)?
Earnings per share at Anhui Huaheng Biotechnology Co. Ltd. A are growing −15.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Anhui Huaheng Biotechnology Co. Ltd. A (688639) generate?
The free cash flow of Anhui Huaheng Biotechnology Co. Ltd. A is −532M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Anhui Huaheng Biotechnology Co. Ltd. A (688639) carry?
The net debt of Anhui Huaheng Biotechnology Co. Ltd. A is 1.8B CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Anhui Huaheng Biotechnology Co. Ltd. A in the live analysis
One click puts Anhui Huaheng Biotechnology Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
